"Experimental" institutional models for corporate funding of academic research: Unknown effects on the research enterprise

Journal of Clinical Epidemiology

Volumn 61, Issue 7, 2008, Pages 629-633

  Bero, Lisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; FUNDING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; METHODOLOGY; PRIORITY JOURNAL; RESEARCH ETHICS; TOBACCO INDUSTRY;

EID: 44449117894     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2008.01.002     Document Type: Note

References (58)

1. Krimsky S. Science in the private interest (2003), Rowan & Littlefield, Lanham, MD
2. Macilwain C. Berkeley teams up with Novartis in $50m plant genomics deal. Nature 396 (1998) 5
3. Bero L. Tobacco industry manipulation of research. Public Health Rep 120 (2005) 200-208
4. Shield M. Policies and positions of other organizations on the funding controversy. TRDRP Newsletter Burning Issues 4 1 (2001) 2 continued on page 4
5. Mayor S. UK universities agree protocol for tobacco company funding. BMJ 329 (2004) 9
6. Cancer Research UK. Terms and conditions and administration information for research grants and awards (2007), Cancer Research UK, London
7. Herman R. Harvard School of Public Health faculty votes not to accept funds from the tobacco companies and subsidiaries (2002), Harvard School of Public Health, Boston, MA
8. Cohen J.E., Ashley M.J., Ferrence R., Brewster J.M., and Goldstein A.O. Institutional addiction to tobacco. Tob Control 8 (1999) 70-74
9. Cohen J. Accepting tobacco funding for research: an overview of the issues. TRDRP Newsletter Burning Issues 6 1 (2003) 7 continued on page 10
10. Egilman D., and Bohme S.R. Corporate corruption of science and its effects on workers and the environment. Int J Occup Environ Health 11 (2005) 331-337
11. Lilienfeld D. The silence: The asbestos industry and early occupational cancer research-a case study. Am J Public Health 81 (1991) 791-800
12. Markowitz G., and Rosner D. Deceit and denial: the deadly politics of industrial pollution (2002), University of California Press, Berkeley, CA
13. Rabin R. Warnings unheeded: a history of childhood lead poisoning. Am J Public Health 79 (1989) 1668-1674
14. Sass J., Castleman B., and Wallinga D. Vinyl chloride: a case study of data suppression and misrepresentation. Environ Health Perspect 113 (2005) 809-812
15. Shamoo A.E., and Resnik D.B. Responsible conduct of research (2003), Oxford University Press, New York, NY
16. Nicklin J.L. Arbitrator tells U. of Delaware to allow grant requests to 'racist' fund. Chronicle of Higher Education (1991). http://chronicle.com Available at http://chronicle.com (Sept 4, 1991)
17. King J. Accepting tobacco industry money for research: has anything changed now that harm reduction is on the agenda. [Editorial]. Addiction 101 (2006) 1067-1069
18. Warner K.E. Will the next generation of "safer" cigarettes be safer?. J Pediatr Hematol Oncol 27 (2005) 543-550
19. McDaniel P., Smith E., and Malone R. Philip Morris's Project Sunrise: weakening tobacco control by working with it. Tobacco Control 15 (2006) 215-223
20. Campbell E.G., Powers J.B., Blumenthal D., and Biles B. Inside the triple helix: technology transfer and commercialization in the life sciences. Health Aff (Millwood) 23 (2004) 64-76
21. Kennedy D. Bayh-Dole: almost 25. Science 307 5714 (2005) 1375
22. Schofield A.R. The demise of Bayh-Dole protections against the Pharmaceutical Industry's abuses of government-funded inventions. J Law Med Ethics 32 (2004) 777-783
23. Boettiger S., and Bennett A.B. Bayh-Dole: if we knew then what we know now. Nat Biotechnol 24 (2006) 320-323
24. Reczek P.R. Research and the Bayh-Dole act. Science 303 5654 (2004) 40
25. Thursby J.G., and Thursby M.C. Intellectual property. University licensing and the Bayh-Dole Act. Science 301 5636 (2003) 1052
26. Mello M.M., Clarridge B.R., and Studdert D.M. Academic medical centers' standards for clinical-trial agreements with industry. N Engl J Med 352 (2005) 2202-2210
27. Boyd E., and Bero L. Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions. Sci Eng Ethics 13 (2007) 415-435
28. Boyd E.A., and Bero L.A. Assessing faculty financial relationships with industry: a case study. JAMA 284 (2000) 2209-2214
29. Boyd E.A., Cho M.K., and Bero L.A. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 78 (2003) 769-774
30. Boyd E.A., Lipton S.A., and Bero L.A. The implementation of financial disclosure policies to manage conflicts of interest. Health Affairs 23 (2004) 206-214
31. Blumenthal D., Campbell E.G., Gokhale M., Yucel R., Clarridge B., Hilgartner S., et al. Data withholding in genetics and the other life sciences: prevalences and predictors. Acad Med 81 (2006) 137-145
32. Campbell E.G., Clarridge B.R., Gokhale M., Birenbaum L., Hilgartner S., Holtzman N.A., et al. Data withholding in academic genetics: evidence from a national survey. JAMA 287 (2002) 473-480
33. Vogeli C., Yucel R., Bendavid E., Jones L.M., Anderson M.S., Louis K.S., et al. Data withholding and the next generation of scientists: results of a national survey. Acad Med 81 (2006) 128-136
34. Barnes D.E., and Bero L.A. Scientific quality of original research articles on environmental tobacco smoke. Tob Control 6 (1997) 19-26
35. Barnes D.E., and Bero L.A. Why review articles on the health effects of passive smoking reach different conclusions. JAMA 279 (1998) 1566-1570
36. Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health 24 (2003) 267-288
37. Lexchin J., Bero L.A., Djulbegovic B., and Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326 7400 (2003) 1167-1170
38. Bekelman J., Li Y., and Gross C. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289 (2003) 454-465
39. Cho M.K., and Bero L.A. The quality of drug studies published in symposium proceedings. Ann Intern Med 124 (1996) 485-489
40. Levine J., Gussow J., Hastings D., and Eccher A. Authors' financial relationships with the food and beverage industry and their published positions on the fat substitute Olestra. Am J Public Health 93 (2003) 664-669
41. Lesser L., Ebbeling C., Goozner M., Wypij D., and Ludwig D. Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Med 4 (2007) e5
42. Bero L.A., and Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care 12 (1996) 209-237
43. Cho M., Shohara R., and Rennie D. Policies on faculty conflicts of interest at US universities. JAMA 284 (2000) 2203-2208
44. DeAngelis C.D. Conflict of interest and the public trust. JAMA 284 (2000) 2237-2238
45. Blumenthal D. Ethics issues in academic-industry relationships in the life sciences: the continuing debate. Acad Med 71 (1996) 1291-1296
46. Frankel M.S. Perception, reality, and the political context of conflict of interest in university-industry relationships. Acad Med 71 (1996) 1297-1304
47. Thompson D.F. Understanding financial conflicts of interest. N Engl J Med 329 (1993) 573-576
48. Blumenthal D., Campbell E., Anderson M., Causino N., and Louis K. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 277 (1997) 1224-1228
49. Campbell E.G., Louis K.S., and Blumenthal D. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. JAMA 279 (1998) 995-999
50. Cho M.K., Illangasekare S., Weaver M.A., Leonard D.G., and Merz J.F. Effects of patents and licenses on the provision of clinical genetic testing services. J Mol Diagn 5 (2003) 3-8
51. Buchting F.O. The tobacco industry as a funder of scientific research: isn't that like leaving the fox in charge of the hen house?. TRDRP Newsletter Burning Issues 4 1 (2001) 3 continued on page 5
52. Hildebrand-Zanki S. Tobacco industry funding: implications for the scientific community. TRDRP Newsletter Burning Issues 4 1 (2001) 1 continued on page 5
53. Cohen J.E. Universities and tobacco money: some universities are accomplices in the tobacco epidemic. BMJ 323 (2001) 1-2
54. Bandura A. Mechanisms of Moral Disengagement. In: Reich W. (Ed). Origins of terrorism: psychology, ideologies, states of mind (1990), Cambridge University Press, Cambridge, MA
55. Bandura A., Barbaranelli C., Cappara G.V., and Pastorelli C. Mechanisms of moral disengagement in the exercise of moral agency. J Pers Soc Psychol 71 (1996) 364-374
56. Bandura A. Moral disengagement in the perpetration of inhumanities. Pers Soc Psychol Rev 3 (1999) 193-209
57. Bandura A., Cappara G.V., and Zsolnai L. Corporate transgressions through moral disengagement. J Hum Values 6 (2000) 57-64
58. Malone R.E., and Bero L.A. Chasing the dollar: why scientists should decline tobacco industry funding. J Epidemiol Community Health 57 (2003) 546-548